Cargando…
Development of common variable immunodeficiency in IgA- and IgG2-deficient patients with systemic lupus erythematosus
BACKGROUND: There have been few reports on children who developed common variable immunodeficiency (CVID) in association with immunoglobulin A (IgA) and IgG2 deficiencies and systemic lupus erythematosus (SLE). CASE-DIAGNOSIS/TREATMENT: Our patient experienced nephrotic syndrome and acute respirator...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101897/ https://www.ncbi.nlm.nih.gov/pubmed/22207346 http://dx.doi.org/10.1007/s00467-011-2063-y |
_version_ | 1783511716146970624 |
---|---|
author | Suyama, Kazuhide Kawasaki, Yukihiko Abe, Yusaku Watanabe, Masahiro Ohara, Shinichiro Oikawa, Tomoko Sakai, Nobuko Hashimoto, Kouichi Hosoya, Mitsuaki |
author_facet | Suyama, Kazuhide Kawasaki, Yukihiko Abe, Yusaku Watanabe, Masahiro Ohara, Shinichiro Oikawa, Tomoko Sakai, Nobuko Hashimoto, Kouichi Hosoya, Mitsuaki |
author_sort | Suyama, Kazuhide |
collection | PubMed |
description | BACKGROUND: There have been few reports on children who developed common variable immunodeficiency (CVID) in association with immunoglobulin A (IgA) and IgG2 deficiencies and systemic lupus erythematosus (SLE). CASE-DIAGNOSIS/TREATMENT: Our patient experienced nephrotic syndrome and acute respiratory distress syndrome (ARDS) caused by influenza A/H1N1 virus infection at 5 years of age. A diagnosis of IgA and IgG2 deficiency and SLE was made on the basis of severe proteinuria, hematuria, hypocomplementemia, high anti-DNA antibody and antinuclear antibody (ANA) titers, and malar rash. However, these clinical signs and symptoms and laboratory features disappeared after the administration of methylprednisolone pulse therapy and prednisolone. For the 5 years following the initial treatment for SLE, the patient experienced a number of infections and had a low serum total IgG level; she was eventually diagnosed with CVID. The administration of intravenous immunoglobulin (IVIG) was required to prevent subsequent infections, and no relapse of SLE was observed. CONCLUSION: We report the development of CVID in an IgA- and IgG2-deficient patient with SLE on the basis of multiple episodes of infection. To prevent the development of CVID in IgA- and IgG2-deficient patients with SLE, it is important to prevent immune dysregulation by the avoidance of infections through the use of IVIG therapy. |
format | Online Article Text |
id | pubmed-7101897 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Springer-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-71018972020-03-31 Development of common variable immunodeficiency in IgA- and IgG2-deficient patients with systemic lupus erythematosus Suyama, Kazuhide Kawasaki, Yukihiko Abe, Yusaku Watanabe, Masahiro Ohara, Shinichiro Oikawa, Tomoko Sakai, Nobuko Hashimoto, Kouichi Hosoya, Mitsuaki Pediatr Nephrol Brief Report BACKGROUND: There have been few reports on children who developed common variable immunodeficiency (CVID) in association with immunoglobulin A (IgA) and IgG2 deficiencies and systemic lupus erythematosus (SLE). CASE-DIAGNOSIS/TREATMENT: Our patient experienced nephrotic syndrome and acute respiratory distress syndrome (ARDS) caused by influenza A/H1N1 virus infection at 5 years of age. A diagnosis of IgA and IgG2 deficiency and SLE was made on the basis of severe proteinuria, hematuria, hypocomplementemia, high anti-DNA antibody and antinuclear antibody (ANA) titers, and malar rash. However, these clinical signs and symptoms and laboratory features disappeared after the administration of methylprednisolone pulse therapy and prednisolone. For the 5 years following the initial treatment for SLE, the patient experienced a number of infections and had a low serum total IgG level; she was eventually diagnosed with CVID. The administration of intravenous immunoglobulin (IVIG) was required to prevent subsequent infections, and no relapse of SLE was observed. CONCLUSION: We report the development of CVID in an IgA- and IgG2-deficient patient with SLE on the basis of multiple episodes of infection. To prevent the development of CVID in IgA- and IgG2-deficient patients with SLE, it is important to prevent immune dysregulation by the avoidance of infections through the use of IVIG therapy. Springer-Verlag 2011-12-30 2012 /pmc/articles/PMC7101897/ /pubmed/22207346 http://dx.doi.org/10.1007/s00467-011-2063-y Text en © IPNA 2011 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Brief Report Suyama, Kazuhide Kawasaki, Yukihiko Abe, Yusaku Watanabe, Masahiro Ohara, Shinichiro Oikawa, Tomoko Sakai, Nobuko Hashimoto, Kouichi Hosoya, Mitsuaki Development of common variable immunodeficiency in IgA- and IgG2-deficient patients with systemic lupus erythematosus |
title | Development of common variable immunodeficiency in IgA- and IgG2-deficient patients with systemic lupus erythematosus |
title_full | Development of common variable immunodeficiency in IgA- and IgG2-deficient patients with systemic lupus erythematosus |
title_fullStr | Development of common variable immunodeficiency in IgA- and IgG2-deficient patients with systemic lupus erythematosus |
title_full_unstemmed | Development of common variable immunodeficiency in IgA- and IgG2-deficient patients with systemic lupus erythematosus |
title_short | Development of common variable immunodeficiency in IgA- and IgG2-deficient patients with systemic lupus erythematosus |
title_sort | development of common variable immunodeficiency in iga- and igg2-deficient patients with systemic lupus erythematosus |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101897/ https://www.ncbi.nlm.nih.gov/pubmed/22207346 http://dx.doi.org/10.1007/s00467-011-2063-y |
work_keys_str_mv | AT suyamakazuhide developmentofcommonvariableimmunodeficiencyinigaandigg2deficientpatientswithsystemiclupuserythematosus AT kawasakiyukihiko developmentofcommonvariableimmunodeficiencyinigaandigg2deficientpatientswithsystemiclupuserythematosus AT abeyusaku developmentofcommonvariableimmunodeficiencyinigaandigg2deficientpatientswithsystemiclupuserythematosus AT watanabemasahiro developmentofcommonvariableimmunodeficiencyinigaandigg2deficientpatientswithsystemiclupuserythematosus AT oharashinichiro developmentofcommonvariableimmunodeficiencyinigaandigg2deficientpatientswithsystemiclupuserythematosus AT oikawatomoko developmentofcommonvariableimmunodeficiencyinigaandigg2deficientpatientswithsystemiclupuserythematosus AT sakainobuko developmentofcommonvariableimmunodeficiencyinigaandigg2deficientpatientswithsystemiclupuserythematosus AT hashimotokouichi developmentofcommonvariableimmunodeficiencyinigaandigg2deficientpatientswithsystemiclupuserythematosus AT hosoyamitsuaki developmentofcommonvariableimmunodeficiencyinigaandigg2deficientpatientswithsystemiclupuserythematosus |